Germany
IonGate Biosciences, a Germany-based screening technology firm, has launched a partnership with the country's Federal Ministry of Education and Research (BMBF) to develop SURFE2R, a proprietary technology platform for the investigation of transporter proteins, over a three-year period.
IonGate described the purpose of the research program as a biological mechanism for the elimination of drugs and their metabolites. The firm said: "there is strong interest from the pharmaceutical industry to assess this biological mechanism in a quantitative way in order to evaluate the elimination and safety profile of compounds in preclinical development."
Thiemo Gropp, IonGate's chief executive, said: "we are delighted to participate in this competence network which brings functional, bioinformatic and genomic expertise together to create a unique toolset for rapid preclinical screening of pharmacological compounds." Dr Gropp added that, "ultimately, this toolset will speed up the drug development process and increase drug safety by reducing and predicting side effects."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze